PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREBPPAR-γCD36 Pathway
Joint Authors
Hu, Peng
Liu, Yu
Cheng, Fei
Luo, Yuxuan
Zhan, Zhu
Ren, Hong
Tang, Huadong
Peng, Mingli
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-07-09
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Curcumin has the potential to cure dyslipidemia and nonalcoholic fatty liver disease (NAFLD).
However, its therapeutic effects are curbed by poor bioavailability.
Our previous work has shown that modification of curcumin with polyethylene glycol (PEG) improves blood concentration and tissue distribution.
This study sought to investigate the role of a novel PEGylated curcumin derivative (Curc-mPEG454) in regulating hepatic lipid metabolism and to elucidate the underlying molecular mechanism in a high-fat-diet- (HFD-) fed C57BL/6J mouse model.
Mice were fed either a control chow diet (D12450B), an HFD (D12492) as the NAFLD model, or an HFD with Curc-mPEG454 administered by intraperitoneal injection at 50 mg/kg or 100 mg/kg for 16 weeks.
We found that Curc-mPEG454 significantly lowered the body weight and serum triglyceride (TG) levels and reduced liver lipid accumulation in HFD-induced NAFLD mice.
It was also shown that Curc-mPEG454 suppressed the HFD-induced upregulated expression of CD36 and hepatic peroxisome proliferator activated receptor-γ (PPAR-γ), a positive regulator of CD36.
Moreover, Curc-mPEG454 dramatically activated cAMP response element-binding (CREB) protein, which negatively controls hepatic PPAR-γ expression.
These findings suggest that Curc-mPEG454 reverses HFD-induced hepatic steatosis via the activation of CREB inhibition of the hepatic PPAR-γ/CD36 pathway, which may be an effective therapeutic for high-fat-diet-induced NAFLD.
American Psychological Association (APA)
Liu, Yu& Cheng, Fei& Luo, Yuxuan& Zhan, Zhu& Hu, Peng& Ren, Hong…[et al.]. 2017. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREBPPAR-γCD36 Pathway. BioMed Research International،Vol. 2017, no. 2017, pp.1-11.
https://search.emarefa.net/detail/BIM-1138984
Modern Language Association (MLA)
Liu, Yu…[et al.]. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREBPPAR-γCD36 Pathway. BioMed Research International No. 2017 (2017), pp.1-11.
https://search.emarefa.net/detail/BIM-1138984
American Medical Association (AMA)
Liu, Yu& Cheng, Fei& Luo, Yuxuan& Zhan, Zhu& Hu, Peng& Ren, Hong…[et al.]. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREBPPAR-γCD36 Pathway. BioMed Research International. 2017. Vol. 2017, no. 2017, pp.1-11.
https://search.emarefa.net/detail/BIM-1138984
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1138984